Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?

Cardiovasc Diabetol · 2004 · PMC538252 · PMID 15574199

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Ingeneral, the incidence of coronary heart disease in patients on bezafibrate has tended to be lower , but this tendency did not reach statistical significance.

also in 111,027 other papers

an overall trendno p-value reported

In the Bezafibrate Infarction Prevention (BIP) study an overall trend of a 9.4% reduction of the incidence of primary end point (fatal or non-fatal myocardial infarction or sudden death) was observed.

also in 4,871 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.